Clinical Trials Logo

Malignant Solid Neoplasm clinical trials

View clinical trials related to Malignant Solid Neoplasm.

Filter by:

NCT ID: NCT05198089 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients With Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to pilot a beta version of a digital resource that supports the religious and spiritual beliefs of cancer patients, "MyInspiration".After receiving a cancer diagnosis, survivors are encouraged to make major life-altering decisions related to their treatment and care. The availability of spiritual/religious resources during cancer treatment may positively impact patient outcomes, feelings of well-being, and be essential components of holistic, patient-centered care. MyInspiration is a digital tool focused on spiritual and/or religious guidance and support that can be customized based on patient preferences and administered to cancer patients and their family members during cancer treatment. MyInspiration may help improve spiritual well-being in patients with cancer.

NCT ID: NCT05173961 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy

Start date: June 29, 2022
Phase: N/A
Study type: Interventional

This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex. The technology, daily treatments, and possible side effects can be confusing to prevent and manage. Traditional radiation patient education includes a large amount of information, including details of treatment logistics, side effect prevention, and management. However, this information is not always readily accessible or memorable through the long course of therapy, and critical details can be missed. Oncpatient is a mobile application intended to be a more convenient and accessible form of patient education and guidance that is readily available to help patients and their caretakers navigate through radiation treatment.

NCT ID: NCT05103358 Active, not recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT05102656 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

Start date: June 2, 2021
Phase:
Study type: Observational

This study investigates patients' perceptions of their doctor's or nurse's empathy during an in-person interaction with the doctor or nurse wearing personal protective equipment (PPE) compared to during a video interaction with the doctor or nurse without PPE. The goal of this research study is to learn whether patients who visit the Acute Cancer Care Center at MD Anderson believe they get better (more empathetic) care from doctors who visit them in person wearing PPE or from doctors who visit them by video call and do not wear PPE.

NCT ID: NCT05055011 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer

Start date: December 3, 2020
Phase:
Study type: Observational

This study investigates parents' attitudes and beliefs on the risks of opioid use in children with cancer. Pain is the common symptom reported by pediatric cancer patients. Opioids are the mainstay in the treatment of cancer-related pain. Despite an almost universal desire to prevent or mitigate pain in their children, parents exhibit complex behaviors from withholding prescribed opioids entirely to giving less than the prescribed analgesic dose of opioid to discontinuing despite ongoing pain. Information gathered from this study may help address a crucial knowledge gap in researchers' understanding of parental attitudes and beliefs regarding the risks associated with opioid use in children and adolescents.

NCT ID: NCT05023993 Active, not recruiting - Prediabetes Clinical Trials

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

Start date: June 23, 2022
Phase: N/A
Study type: Interventional

This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.

NCT ID: NCT04940299 Active, not recruiting - Metastatic Melanoma Clinical Trials

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Start date: September 23, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tocilizumab is a monoclonal antibody that may interfere with the immune system to decrease immune-related toxicities. Giving tocilizumab, ipilimumab, and nivolumab may kill more tumor cells.

NCT ID: NCT04905082 Active, not recruiting - Breast Carcinoma Clinical Trials

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Start date: December 30, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.

NCT ID: NCT04865133 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

Start date: March 31, 2021
Phase:
Study type: Observational

This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more regarding how long an immune response will last compared to healthy individuals.

NCT ID: NCT04742595 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

Start date: December 18, 2020
Phase: Early Phase 1
Study type: Interventional

This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for coronavirus disease 2019 (COVID-19). SARS-CoV-2 Specific CTLs are a type of immune cells that are made from donated blood cells grown in the laboratory and are designed to kill cells infected with SARS-CoV-2 virus. Giving CTLs may help control the COVID-19 in cancer patients.